Bryan Garnier raised the price target for the Travere Therapeutics Inc. (NASDAQ:TVTX) stock to “a Sell”. The rating was released on September 21, 2022, according to finviz. We previously noted in another research note published on July 14, 2022 by Canaccord Genuity that resumed the stock to a Buy with a price target of $42 for TVTX stock. The research report from Piper Sandler has initiated the stock to Overweight, with a price target set at $42. The stock was initiated by H.C. Wainwright, who disclosed in a research note on February 28, 2022, to Buy and set the price objective to $45. In their research brief published May 26, 2021, Wedbush analysts downgraded the Travere Therapeutics Inc. stock from Outperform to Neutral with a price target of $19.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Travere Therapeutics Inc. (NASDAQ:TVTX) dipped -2.37% to close Wednesday’s market session at $19.33, lower as compared to yesterday’s close. The stock price fluctuated between $19.25 and $20.21 throughout the trading session with the volume trading being 486572 shares, which represented a significant variation when compared to the three months average volume of 744.48K shares. The firm’s stock price fluctuated -8.65% within the last five trades and -13.51% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -12.42% in the last 6 months and -31.98% was subtracted to its value over the previous 3 months. TVTX stock is trading at a margin of -9.25%, -16.29% and -22.75% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, TVTX deals in the Healthcare domain. The stock is trading -38.93 percent below its 52-week high and 0.62 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -37.8. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Travere Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $1.25 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 5.84 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 12.31, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Heerma Peter, the Chief Commercial Officer at Travere Therapeutics Inc. (TVTX) has sold 3,042 shares of firm on Oct 04 at a price of $25.68 against the total amount of $78119.0. In another inside trade, Calvin Sandra, SVP, Chief Accounting Officer of Travere Therapeutics Inc. (NASDAQ:TVTX) sold 349 shares of the firm on Sep 13 for a total worth of $9772.0 at a price of $28.00. An inside trade which took place on May 12, SVP, GC & Corporate Secretary of Travere Therapeutics Inc. REED ELIZABETH E sold 1,050 shares of firm against total price of $22584.0 at the cost of $21.51 per share.